Core Viewpoint - The company is engaged in the research, production, sales, and service of medical device products, focusing on life information and support as well as nephrology medical sectors, with an expected net loss but a narrowing of losses compared to the previous year [5] Group 1: Financial Performance - The company anticipates a continued net loss during the reporting period, although the loss margin is expected to be smaller than the same period last year [5] - Revenue is projected to show slight growth, driven by enhanced management and operational efficiency [5] - The primary reason for the inability to achieve profitability is a decline in sales prices due to market competition, coupled with rising raw material costs, leading to a decrease in overall gross margin [5] Group 2: Cost Management and Impacts - The company is actively pursuing cost control and efficiency improvements, resulting in a year-on-year reduction in various expenses [5] - However, foreign exchange losses due to the depreciation of the US dollar against the Chinese yuan and high amortization costs related to convertible bonds significantly impact net profit [5] - The company has made provisions for asset impairment on inventory and certain production equipment based on prudence principles, which will affect the current net profit [5] Group 3: Future Projections - For 2025, the expected impact of non-recurring gains and losses on net profit is approximately 8.07 million yuan, primarily from government subsidies [5]

本年度公司主营业务保持稳健的发展，但因各产业技术平台战略发展，整体培育期间持续投入较大，汇 兑损失及利息收入对利润的贡献减少，同时计提资产相关折旧摊销费用，计提部分资产减值损失等原 因，使得2025年度净利润亏损。 智通财经APP讯，东方生物(688298.SH)发布2025年年度业绩预亏公告，预计2025年年度实现归属于母 公司所有者的净利润将出现亏损，实现归属于母公司所有者的净利润-5.23亿元。 ...

Core Viewpoint - Dongfang Biological (688298.SH) announced a projected net loss of 523 million yuan for the fiscal year 2025, attributed to significant investments in strategic development across various technology platforms, foreign exchange losses, reduced interest income contributions, and increased asset depreciation and impairment losses [1] Group 1 - The company expects a net profit attributable to shareholders of the parent company to be -523 million yuan for the year 2025 [1] - The main business of the company continues to develop steadily despite the anticipated losses [1] - The losses are primarily due to ongoing substantial investments in the cultivation period of various industry technology platforms [1] Group 2 - Foreign exchange losses and a decrease in contributions from interest income have negatively impacted profits [1] - The company has also incurred increased depreciation and amortization expenses related to assets [1] - There are provisions for impairment losses on certain assets contributing to the overall net loss [1]

澳华内镜(688212.SH)发布公告，公司预计2025年度实现归属于母公司所有者的净利润为805万元到1158 万元，与上年同期相比，将减少943.22万元到1,296.22万元，同比下降44.89%到61.69%。 ...

证券之星消息，截至2026年1月29日收盘，春立医疗(688236)报收于25.25元，上涨0.12%，换手率 0.86%，成交量2.48万手，成交额6374.46万元。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451.86万元，同比上升439.4%；负债率15.65%，投资收益321.7万元，财务费用-972.34万元，毛 利率67.27%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与销售。 该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为31.9。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于 ...

Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance, with revenue growth but a decline in net profit for the third quarter of 2025 [2] - As of January 29, 2026, Xinmai Medical's stock closed at 94.72 yuan, with a slight increase of 0.77% and a trading volume of 21,600 shares, resulting in a total transaction amount of 204 million yuan [1] - In the recent funding flow data, the main funds experienced a net outflow of 12.5 million yuan, accounting for 6.11% of the total transaction amount, while retail investors saw a net inflow of 6.98 million yuan, representing 3.41% of the total [1] Group 2 - For the first three quarters of 2025, Xinmai Medical reported a main revenue of 1.015 billion yuan, reflecting a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] - The third quarter of 2025 alone saw a significant revenue increase of 64.68% year-on-year, reaching 300 million yuan, although the net profit for that quarter fell by 23.63% to 114 million yuan [2] - The company has a debt ratio of 15.85%, with investment income reported at 11.6 million yuan and a gross profit margin of 70.4% [2]

智通财经APP讯，澳华内镜(688212.SH)发布公告，公司预计2025年度实现归属于母公司所有者的净利 润为805万元到1158万元，与上年同期相比，将减少943.22万元到1,296.22万元，同比下降44.89%到 61.69%。 ...

近5日资金流向一览见下表： 证券之星消息，截至2026年1月29日收盘，新华医疗(600587)报收于16.03元，下跌0.19%，换手率 2.09%，成交量12.63万手，成交额2.03亿元。 1月29日的资金流向数据方面，主力资金净流出473.84万元，占总成交额2.34%，游资资金净流入476.58 万元，占总成交额2.35%，散户资金净流出2.74万元，占总成交额0.01%。 该股最近90天内共有2家机构给出评级，增持评级2家；过去90天内机构目标均价为20.0。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 ...

深圳北芯生命科技股份有限公司 首次公开发行股票并在科创板上市 发行结果公告 保荐人（主承销商）：中国国际金融股份有限公司 深圳北芯生命科技股份有限公司（以下简称"北芯生命"、"发行人"或"公 司"）首次公开发行人民币普通股（A 股）并在科创板上市（以下简称"本次发 行"）的申请已经上海证券交易所（以下简称"上交所"）上市审核委员会审议通 过，并已经中国证券监督管理委员会同意注册（证监许可〔2025〕2790 号）。发 行人的股票简称为"北芯生命"，扩位简称为"北芯生命"，股票代码为"688712"。 本次发行采用向参与战略配售的投资者定向配售（以下简称"战略配售"）、 网下向符合条件的投资者询价配售（以下简称"网下发行"）、网上向持有上海市 场非限售 A 股股份和非限售存托凭证市值的社会公众投资者定价发行（以下简 称"网上发行"）相结合的方式进行。 中国国际金融股份有限公司（以下简称"中金公司"或"保荐人（主承销商）"） 担任本次发行的保荐人（主承销商）。 发行人与保荐人（主承销商）根据初步询价结果，综合评估发行人合理投资 价值、可比公司二级市场估值水平、所属行业二级市场估值水平等方面，充分考 虑网下投资者有 ...

| | 本次发行基本情况 | | --- | --- | | 股票种类 | 股） 人民币普通股（A | | 每股面值 | 人民币 1.00 元 | | 发行股数 | 本次公开发行股票数量为 万股，占发行后总股本的比例 5,700.0000 | | | 约为 13.67%，本次发行全部为发行新股，不涉及公司股东公开发售 | | | 股份 | | 本次发行价格 | 元/股 17.52 | | 发行人高级管理人员、 | 发行人的高级管理人员与核心员工通过中金北芯生命 1 号员工参与 | | 员工参与战略配售情 | 战略配售集合资产管理计划（以下简称"中金北芯生命 1 号资产管 | | 况 | 理计划"）参与本次战略配售，参与战略配售的数量为 万 570.0000 | | | 股，占本次发行数量的 元。中 10.00%，认购金额为 99,864,000.00 | 1 深圳北芯生命科技股份有限公司 首次公开发行股票并在科创板上市 招股说明书提示性公告 保荐人（主承销商）：中国国际金融股份有限公司 扫描二维码查阅公告全文 深圳北芯生命科技股份有限公司（以下简称"北芯生命"、"发行人"或 "公司"）首次公开发行人民币普通股 ...